ASP Isotopes 3Q 2026: Revenue $5.12M, EPS ($0.21) — 10-Q Summary
ASP Isotopes reported 3Q 2026 revenue of $5.12M, up 303% YoY, driven by radiopharmacy sales and new LNG revenue. However, net loss widened to $30.37M, with higher operating and interest expenses. Gross profit improved, but helium and LNG segment recorded a $0.8M loss. Isotope shipments are planned for 2026-2027, with LNG margins expected to improve in 2027.
How this was made

The 30-second read
Why it matters
Radiopharmacy revenue rose sharply with improved gross margin, while helium/LNG remained loss-making with negative gross margin. The company also notes Phase 1 commercial LNG operations started and expects margin improvement in 2027 as volumes increase.
Market read
Traders may reassess near-term profitability risk versus longer-dated margin improvement tied to LNG volume ramp and isotope shipment timing.
What to watch
The article flags helium and LNG as still below fixed-cost absorption levels, so near-term valuation may hinge more on volume ramp execution than on current revenue growth.
Background
The piece summarizes ASP Isotopes’ 3Q 2026 Form 10-Q, including revenue/EPS and segment updates (radiopharmacies, helium/LNG, isotope shipments).
Ticker impact
ASP Isotopes reports 3Q 2026 revenue of $5.12M and diluted EPS of ($0.21), with radiopharmacy growth and wider shareholder loss.
Likely mixed reaction, with upside from revenue growth offset by continued widening losses and weak helium/LNG economics.
The article provides specific quarterly financials and segment margin details, but it is a 10-Q summary where the market may already be positioned for the filing.
Market effects
Highlights ongoing margin pressure in helium/LNG production until volumes rise, relevant for niche isotope and radiopharma supply-chain expectations.
No clear regional market transmission beyond US-listed small-cap biotech/industrial specialty.
Limited, as the disclosure is company-specific and not tied to a global policy or commodity shock.
Counterpoint
The widened loss may be driven by operating and interest expense timing, while gross profit improved and LNG phase 1 has commenced, which could improve margins later.
Key entities
- companyASP Isotopes Inc.
US-listed isotope and radiopharmacy company reporting 3Q 2026 results and segment performance in a 10-Q summary.
- projectVirginia Gas Project
Phase 1 commenced commercial LNG operations, with expected margin improvement in 2027 as production volumes increase.
